NCT07566286NARecruitingAccepts Healthy Volunteers
Study to Evaluate the Safety of Retreatment With Restylane® Lyft With Lidocaine for Augmentation of the Chin Region
Galderma R&D
Start Date
6/3/2026
Completion Date
2/28/2028
Summary
The primary objective of this study is to evaluate the safety of Restylane Lyft with Lidocaine for augmentation of the chin region 3 months after retreatment.
Eligibility Criteria
Age Range: 22 years to No maximum
Inclusion Criteria:
1. Males or non-pregnant, non-breastfeeding females, 22 years of age or older.
2. Intent to receive treatment for augmentation and correction of retrusion in the chin region.
Exclusion Criteria:
1. Known/previous allergy or hypersensitivity to any injectable hyaluronic acid (HA) gel or to gram positive bacterial proteins.
2. Known/previous allergy or hypersensitivity to local anesthetics, e.g. lidocaine or other amide-type anesthetics.
3. Previous or present multiple allergies or severe allergies, such as manifested by anaphylaxis or angioedema, or family history of these conditions.
4. Previous facial surgery (including facial aesthetic surgery and liposuction), below the level of the horizontal line from subnasale.
5. Any previous aesthetic procedures or implants.
6. Presence of any disease or lesions near or on the area to be treated.
Interventions
DEVICE
Restylane Lyft with Lidocaine
Conditions
Chin Augmentation
Locations
Galderma Investigational Site # 8680
Westport, Connecticut 06880
United States
Galderma Investigational Site # 8774
Boynton Beach, Florida 33437
United States
Galderma Investigational Site # 7030
Coral Gables, Florida 33134
United States
Galderma Investigational Site # 8682
Coral Gables, Florida 33134
United States
Galderma Investigational Site # 7042
Atlanta, Georgia 30331
United States
Galderma Investigational Site # 7043
Bethesda, Maryland 20852
United States
Galderma Investigational Site # 7118
Nashville, Tennessee 37203
United States
Galderma Investigational Site # 8662
Spring, Texas 77388
United States